

Humedics appoints Erwin de Buijzer as managing director for marketing and sales

Berlin, Germany, May 4, 2012 - Humedics GmbH, a specialist for real-time and mobile measurement of the individual liver function at the bedside of the patient, today announced that Erwin de Buijzer MD MBA has joined Humedics as managing director to support the further development and strategic positioning of the company.

Erwin de Buijzer is a seasoned Healthcare manager with significant experience in medical marketing and strategy. He held various positions at Eurotransplant and the Dutch Transplant Foundation, as well as in medical marketing at Abbott Laboratories and Nutrica Advanced Medical Nutrition as Medical Director. Before his industry career he worked as a medical doctor in the ICU and in surgery. He received his Medical Doctor degree from the Erasmus University in Rotterdam, The Netherlands, and has an MBA from the Rotterdam School of Management.

“We are very pleased that Erwin has joined the management team of Humedics”, said Klaus Stoeckemann, Chairman of Humedics’ board and Managing Director at Peppermint VenturePartners. He brings the relevant skills and spirit to the founder team allowing to accomplishing the finalization of the FLIP™ device, the development of ¹³C-Methacetin and making the LiMAx™ test the standard of care in liver diagnostics”.

About Humedics

Humedics has developed a breath test (LiMAx™ test) based diagnostic system composed of the medical device FLIP™ and a new diagnostic drug preparation (¹³C-Methacetin). More than 100 million people world-wide suffer from chronic liver diseases (i.e. cirrhosis, hepatitis, fatty liver, metabolic disorders and tumors). The LiMAx™ test enables the clinician to quantitatively determine the individual liver function capacity within minutes. This allows for selecting treatment strategies optimally adapted to the individual patients liver status. Current applications include diagnosis of the liver function before and after liver transplantation, liver surgery and assessment of diseases of the liver such as liver cirrhosis. Up to date the LiMAx™ test has been validated in over 7,500 tests and the results have been published in highly respected scientific journals. In 2011 Humedics completed its first equity financing round with Peppermint VenturePartners (managing the Charité Biomedical Fund) as lead investor together with VC Fonds Technologie managed by IBB-Beteiligungsgesellschaft, ERP Startfonds of the KfW, Ventegis and current investor High-Tech Gründerfonds. The funds enable Humedics to complete the final development and early commercialization of its proprietary and CE-marked diagnostic system to determine the liver function of a patient in real time.

Humedics Contact:

Humedics GmbH
Marie-Elisabeth-Lüders Str. 1
10625 Berlin
Phone: +49 30 590083240
E-Mail: info@humedics.de
Homepage: www.humedics.de